In recent trading activity, Teresa McCarthy, the Chief Human Resources Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), sold shares of the company’s common stock, resulting in a total transaction value exceeding $578,000. The sale occurred on September 23, 2024, with the shares being sold at prices ranging from $44.00 to $44.08, averaging $44.0004 per share. This transaction involved a total of 13,153 shares.
The sale was part of a “sell-to-cover” transaction to satisfy tax withholding obligations connected to the vesting of performance-based restricted stock units (PSUs). These PSUs vested upon the achievement of the company’s second performance objective, which was the completion of a clinical event related to the drug candidate del-brax. According to the footnotes in the filing, the sale was mandated by Avidity Biosciences’ equity incentive plans and does not represent a discretionary trade by McCarthy. An instruction letter was executed for the automatic sale of these shares to comply with the affirmative defense conditions of Rule 10b5-1.
In addition to the sale, McCarthy also acquired 25,000 shares of common stock at no cost on September 19, 2024, as a result of the PSUs vesting. These PSUs converted to time-based restricted stock units set to vest in full on March 19, 2025, provided McCarthy remains employed or in service with Avidity Biosciences through that date.
Following these transactions, McCarthy’s direct ownership in the company stands at 69,018 shares of common stock.
Investors and market watchers often scrutinize insider trading activity for signals about a company’s prospects. Avidity Biosciences specializes in the development of pharmaceutical preparations and has been a subject of interest for those following the biotech industry.
In other recent news, Avidity Biosciences announced a $250 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $37.5 million in shares. The proceeds are earmarked for advancing the company’s clinical programs, research, development, and general corporate purposes. Leerink Partners and TD Cowen are managing the proposed offering.
The company also reported positive preliminary results from a Phase 1/2 clinical trial for delpacibart zotadirsen, a potential treatment for Duchenne muscular dystrophy (DMD). Significant increases in dystrophin production and exon 44 skipping were observed, along with a substantial reduction in creatine kinase levels.
In terms of analyst coverage, BofA Securities raised its price target from $40.00 to $45.00 while maintaining a Buy rating on Avidity’s stock. Wells Fargo and Cantor Fitzgerald also reaffirmed their Overweight ratings.
In other company developments, Avidity expanded its board of directors with the appointment of Simona Skerjanec, a pharmaceutical industry veteran. Additionally, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Avidity’s lead investigational drug, delpacibart etedesiran, for the treatment of myotonic dystrophy type 1. These are the recent developments in the company’s journey.
InvestingPro Insights
In light of the recent insider trading activity at Avidity Biosciences, Inc. (NASDAQ:RNA), investors may benefit from considering additional financial metrics and analyst insights. According to real-time data from InvestingPro, Avidity Biosciences has a market capitalization of approximately $5.08 billion. Despite the impressive year-to-date price total return of 380.66%, the company’s revenue for the last twelve months as of Q2 2024 stands at $10.6 million, with a growth rate of 8.15%. However, the company’s gross profit margin during the same period was notably negative at -2082.31%, indicating significant costs relative to its revenue.
InvestingPro Tips suggest that Avidity Biosciences holds more cash than debt on its balance sheet and that its liquid assets exceed short-term obligations, which may be reassuring to investors concerned about the company’s financial stability. On the other hand, analysts have noted weak gross profit margins and expect net income to drop this year, with the consensus being that the company will not be profitable within this period. Despite these challenges, six analysts have revised their earnings estimates upwards for the upcoming period, signaling potential optimism for the company’s future performance.
For those interested in a deeper dive into Avidity Biosciences’ financials and future outlook, there are additional InvestingPro Tips available at https://www.investing.com/pro/RNA. These tips can provide valuable context for the insider transactions and help investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
